CN112280755A - 一种突变酶及其应用和酶催化法制备三胜肽的工艺 - Google Patents

一种突变酶及其应用和酶催化法制备三胜肽的工艺 Download PDF

Info

Publication number
CN112280755A
CN112280755A CN202011231194.8A CN202011231194A CN112280755A CN 112280755 A CN112280755 A CN 112280755A CN 202011231194 A CN202011231194 A CN 202011231194A CN 112280755 A CN112280755 A CN 112280755A
Authority
CN
China
Prior art keywords
leu
ser
ala
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011231194.8A
Other languages
English (en)
Other versions
CN112280755B (zh
Inventor
于铁妹
潘俊锋
刘建
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Readline Biotechnology Co ltd
Original Assignee
Shenzhen Readline Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Readline Biotechnology Co ltd filed Critical Shenzhen Readline Biotechnology Co ltd
Priority to CN202011231194.8A priority Critical patent/CN112280755B/zh
Publication of CN112280755A publication Critical patent/CN112280755A/zh
Priority to EP21888289.2A priority patent/EP4242300A1/en
Priority to US18/035,736 priority patent/US20230407286A1/en
Priority to PCT/CN2021/117378 priority patent/WO2022095590A1/zh
Application granted granted Critical
Publication of CN112280755B publication Critical patent/CN112280755B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • C12N9/104Aminoacyltransferases (2.3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1085Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y603/00Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02003Glutathione synthase (6.3.2.3)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

本发明涉及生化技术领域,公开了一种突变酶及其应用和酶催化法制备三胜肽的工艺。本发明包括甘氨酸和L‑组氨酸连接酶GHS以及三肽连接酶HKS;或为两者的融合酶。本发明通过改造让Lal酶实现甘氨酸、L‑组氨酸连接酶活力从而获得GHS酶,以及让gshB酶实现二肽甘氨酸‑L‑组氨酸与L‑赖氨酸的合成能力从而获得HKS酶。在此基础上,进一步利用多肽链将GHS酶与HKS酶进行融合,则可以构造一次性连接甘氨酸、L‑组氨酸以及L‑赖氨酸的双功能酶GHKS,从而实现方便的、高收率的制备三胜肽;而对于该酶催化反应中所需要的大量ATP,可以采用多聚磷酸激酶进行循环再生,进而大大降低ATP的用量。

Description

一种突变酶及其应用和酶催化法制备三胜肽的工艺
技术领域
本发明涉及生化技术领域,具体涉及一种突变酶及其应用和酶催化法制备三胜肽的工艺。
背景技术
三胜肽(GHK)是由甘氨酰、L-组氨酰与L-赖氨酸连接而成的一种天然三肽化合物(Gly-L-His-L-Lys),其分子式为C14H24N6O4、分子量为340,三胜肽能与等当量铜有效络合而生成铜胜肽。铜是生物体内重要元素,它参与细胞呼吸作用、生物体内抗氧化、解毒、凝血、黑色素以及结缔组织的生成等等重要的生理功能;三胜肽能通过有效络合、转运铜元素而发挥相应的作用,譬如络合的铜胜肽能有效刺激成纤维细胞(fibroblasts)内胶原蛋白的生物合成,从而促进伤口的快速愈合;铜胜肽还能有效阻止乙醯胆碱物质的神经传导,从而具有放松肌肉,改善动态性皱纹等功效。三胜肽现被广泛应用于化妆品添加剂。
市面上三胜肽制备方法主要是分离法与化学合成法。由于三胜肽存在于不少动物体内,其最初的发现及制备则是从大量动物内脏水溶液中提取、分离,该方法分离程序繁琐、产率极低,因而无法实现其规模化生产。化学合成法是现阶段三胜肽工业生产的常见方法,与其它多肽化学合成类似,三胜肽化学制备过程中不可避免需要采用繁琐的官能团选择性保护、缩合以及脱保护等步骤,这不仅大大的增加了其生产成本,同时也会导致部分手性官能团消旋,从而降低产品品质。
与谷胱甘肽(GSH)不同,三胜肽(GHK)虽然也存在于不少动物体内,但是至今没有发现对应的氨基酸连接酶来生产GHK,其来源可能是通过体内多肽或蛋白分级降解而成。但是自然界存在大量的短肽合成酶,如L-氨基酸连接酶(Lal,EC 6.3.2.49),它们被发现能直接连接或者改造后连接多种多样的氨基酸,但经过本发明HPLC检测Lal仅具有很低的甘氨酸及L-组氨酸连接酶活力(最高转化率低于1%),所以不能用来放大生产;与此同时,谷胱甘肽合成酶(gshB,EC 6.3.2.3)也被广泛报道能催化特定二肽与氨基酸的连接从而形成三肽产物,其底物也同样具有多样性。然而经过本发明的实践验证,gshB酶没有甘氨酸-L-组氨酸与L-赖氨酸的合成能力。因此,如何获得对应的氨基酸连接酶来生产GHK是其中最为关键的问题。
发明内容
有鉴于此,本发明的目的在于提供一种突变酶,使其能够实现甘氨酸、L-组氨酸连接酶活力,以及实现二肽甘氨酸-L-组氨酸与L-赖氨酸的合成能力,从而可以利用酶法高效率生产三胜肽;
本发明的另外一个目的在于提供上述突变酶在生产三胜肽中的应用;
本发明的另外一个目的在于提供利用上述突变酶生产三胜肽的方法。
为实现上述目的,本发明提供如下技术方案:
一种突变酶,其特征在于,包括甘氨酸和L-组氨酸连接酶GHS以及三肽连接酶HKS;或为两者的融合酶;
其中,所述甘氨酸和L-组氨酸连接酶GHS为在野生型L-氨基酸连接酶Lal基础上具有T244I、S290L、G292W、E84K、A158H、G159D位点突变的酶;所述三肽连接酶HKS为在野生型谷胱甘肽合成酶gshB基础上具有V150F、S153E、E228I、N230H、D233T、R285V、D130Q、E146L、N148S、G387、I445D位点突变的酶。
本发明针对目前缺少氨基酸连接酶来生产GHK的缺陷,在现有L-氨基酸连接酶(Lal,EC 6.3.2.49)以及谷胱甘肽合成酶(gshB,EC 6.3.2.3)的基础上进行位点突变改造,可实现催化甘氨酸与L-组氨酸连接活力和对二肽甘氨酸-L-组氨酸与L-赖氨酸的合成能力,一步实现酶法催化生成三胜肽的目的。
同时,本发明还将两种突变酶融合,通过连接肽组成融合酶则可以构造一次性连接甘氨酸、L-组氨酸以及L-赖氨酸的双功能酶GHKS,从而实现方便的、高收率的制备三胜肽。在本发明具体实施方式中,所述连接肽序列如SEQ ID No.17或18所示;
本发明中,L-氨基酸连接酶(Lal,EC 6.3.2.49)来源于Pseudomonas syringae、gshB酶(EC 6.3.2.3)来源于Saccharomyces cerevisiae,属于PF02955&PF02951酶家族成员;PPK(EC 2.7.4.1)来源于Paenarthrobacter aurescens,属于PF03976酶家族成员;ADK(EC 2.7.4.3)来源于Escherichia coli,属于PF05191酶家族成员。
通过利用本发明提供的突变酶可以一步实现甘氨酸、L-组氨酸与L-赖氨酸的催化连接生成三胜肽,收率达到62-91%,纯度保持在90%以上,产物杂质少,反应、纯化工艺简便。基于这种优异的技术效果,本发明提供了所述突变酶在催化甘氨酸、L-组氨酸、L-赖氨酸生成三胜肽中的应用或在制备催化甘氨酸、L-组氨酸、L-赖氨酸生成三胜肽的酶制剂中的应用。作为优选,所述酶制剂为表达突变酶的宿主细胞、突变酶的酶液或突变酶的固定化酶。
依据应用,本发明提供了一种酶催化法制备三胜肽的工艺,反应原料甘氨酸、L-组氨酸、L-赖氨酸、ATP或其盐,在本发明所述突变酶的pH值范围内的反应介质中,与所述突变酶进行酶催化反应生成三胜肽。
在反应过程中维持体系pH值在所述突变酶pH值范围内;在本发明具体实施方式中,所述突变酶pH值范围选自为6.5-9.0,但不排除其他的能够发挥所述突变酶功能的pH值范围。作为优选,所述ATP盐为ATP钠盐,如三磷酸腺苷二钠盐,其同样可以提供ATP。
作为优选,所述反应介质为缓冲液;在本发明具体实施方式中,所述缓冲液为为Tris-HCl。
同时,多聚磷酸激酶(PPK,EC 2.7.4.1)能利用廉价的多聚磷酸作为原料将二磷酸腺苷ADP转化成三磷酸腺苷ATP,而腺苷酸激酶(ADK,EC 2.7.4.3)则能实现三种磷酸腺苷(AMP、ADP、ATP)的相互转化,通过联合使用这两个酶或将两个酶融合表达生成(PPK-ADK/ADK-PPK)不仅可以降低酶发酵生产成本,还能有效加快ATP再生速度。因此,本发明工艺还包括添加反应原料PPK和ADK或两者融合蛋白、多聚磷酸、氯化镁和氯化钾(氯化镁和氯化钾用于ATP再生)。具体的反应原理示意图见图1。
本发明所述突变酶、PPK和ADK或两者融合酶(PPK-ADK/ADK-PPK)可以利用表达各酶的宿主细胞、各酶的酶液或各酶的固定化酶形式参与酶催化反应。
与大多数的反应一样,本发明还包括选自除蛋白杂质、除残留反应原料、除盐、除磷酸和结晶中的一种或两种以上操作的纯化步骤,具体选择何种纯化步骤,根据实际情况调整。具体地,酸化处理除去蛋白杂质,反渗透除盐,阴离子交换树酯除含磷酸杂质,结晶通过乙醇水溶液来结晶纯化,更优选为纯水:乙醇(1-3):1v/v来结晶纯化。
由以上技术方案可知,本发明通过改造让Lal酶实现甘氨酸、L-组氨酸连接酶活力,以及让gshB酶实现二肽甘氨酸-L-组氨酸与L-赖氨酸的合成能力。在此基础上,进一步利用多肽链将GHS酶与HKS酶进行融合,则可以构造一次性连接甘氨酸、L-组氨酸以及L-赖氨酸的双功能酶GHKS,从而实现方便的、高收率的制备三胜肽;而对于该酶催化反应中所需要的大量三磷酸腺苷,可以采用多聚磷酸激酶PPK进行循环再生,进而大大降低ATP的用量。
附图说明
图1所示为本发明反应原理示意图;
图2所示为酶纯化后的SDS-PAGE凝胶图;
图3所示为纯化后三胜肽在600M Varian在D2O溶液核磁谱图;上图为1H-NMR,下图为13C-NMR。
具体实施方式
本发明公开了一种突变酶及其应用和酶催化法制备三胜肽的工艺,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明突变酶及其应用和相关工艺已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文突变酶及其应用和相关工艺进行改动或适当变更与组合,来实现和应用本发明技术。
本发明所述工艺的步骤旨在清楚的描述核心的反应路线,并不限制整个反应采用一步法还是多步法进行。
在本发明具体实施方式中,所采用的各酶可以根据序列进行人工合成,本发明中所提及的各酶的序列汇总如下表1:
表1
Figure BDA0002765270130000041
Figure BDA0002765270130000051
Figure BDA0002765270130000061
Figure BDA0002765270130000071
表1中,GHKS-1和GHKS-2为本发明提供的两种融合酶(GHS-HKS,连接肽不同),加粗加下划线氨基酸表示突变位点以及突变后氨基酸,斜体加下划线序列为连接肽序列。
上述各酶也可以通过各自的编码基因构建重组质粒进行细胞转化,例如:
以ATCC购买的大肠杆菌(Escherichia coli K12),酿酒酵母(Saccharomycescerevisiae ATCC 204508)以及保氏杆菌(Paenarthrobacter aurescens TC1)染色体为模板,利用表2引物PCR扩增出扩增出ADK,gshB以及PPK基因片段,然后利用NEB公司购买的NdeI/Xho I进行相应的酶切,并连接到相同切点的pET28a质粒上(购于Addgene),最后进行质粒转化(转入E coli Dh5a细胞,购于擎科生物)并菌落PCR及基因测序验证。La1基因片段是通过公司合成(安徽通用生物)并亚克隆到pET28a质粒上。最后以La1与gshB基因为模板,利用表2突变引物(常规的PCR扩增实现)构建多位点突变酶基因GHS与HKS。将上述构建到pET-28a载体上的GHS,HKS,PPK以及ADK质粒转入E.coli BL21(DE3)(购于安徽通用生物)菌株里,在37℃、5ml含50uM卡那霉素(Kanamycin)的LB培养液中进行小量培养,当细胞生长至OD0.5-0.8加入0.5mM异丙基-β-D-硫代吡喃半乳糖苷(IPTG),37℃诱导蛋白表达3小时,最后收集细胞、冻融法进行细胞破碎、高速离心,收集到的上清液再利用十二烷基磺酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)确认蛋白表达。蛋白表达正确的菌株逐级培养至5升发酵罐,在1.0mM IPTG条件下37℃诱导表达4小时,收集湿细胞近35-55克;最后将细胞与适量的Tris-HCl缓冲液(25mM,pH=8.0)混合均匀后用高压破碎仪低温破碎,高速离心除去细胞壁后酶液保存在4℃冰箱备用。LB培养基构成为:1%胰蛋白胨、0.5%酵母粉,1%NaCl,1%磷酸氢二钾、1%磷酸氢二钾以及5%的甘油。
表2
Figure BDA0002765270130000072
Figure BDA0002765270130000081
各酶可以以含酶的粗酶液、纯化后的酶或固定化酶的方式进行催化反应:
例如:收集的含酶的湿细胞混合在Tris-HCl缓冲液(25mM,pH=8.0)(缓冲液A),搅拌均匀后通过高压破碎细胞,高速离心除去细胞壁,收集到的清液为粗酶液,直接进行后续催化反应;
或者,上述上清液逐渐加入硫酸铵固体直至析出蛋白析出(35%-55%,w/v硫酸铵/缓冲液)。该蛋白固体随后通过高速离心收集(10000rpm,12min),并缓慢溶入Tris-HCl缓冲液(25mM,pH=8.0),经G25脱盐柱(购于Sigma)除盐后经DEAE Seplite FF(西安蓝晓公司)阴离子交换柱分离纯化,最终得到初纯化酶,SDS-PAGE凝胶图见图2。
在进行固定化时,可参照本领域常规的固定化酶制备方式。
依照本发明工艺的反应路线,各反应物质的用量可以根据实际情况调整。
虽然根据本发明提供的酶的序列可以知晓其编码序列,但在本发明中还是提供了如下表3的具体的编码序列:
表3
Figure BDA0002765270130000091
Figure BDA0002765270130000101
Figure BDA0002765270130000111
Figure BDA0002765270130000121
Figure BDA0002765270130000131
Figure BDA0002765270130000141
Figure BDA0002765270130000151
Figure BDA0002765270130000161
下面结合实施例,进一步阐述本发明。
实施例1:催化制备三胜肽(GHS,HKS,PPK,ADK组合)
以ATCC购买的大肠杆菌(Escherichia coli K12),酿酒酵母(Saccharomycescerevisiae ATCC 204508)以及保氏杆菌(Paenarthrobacter aurescens TC1)染色体为模板用上述对应引物PCR扩增出ADK,gshB以及PPK基因片段,然后利用NEB公司购买的Nde I/Xho I进行相应的酶切,并连接到相同切点的pET28a质粒上(购于Addgene),最后进行质粒转化(转入E coli Dh5a细胞,购于擎科生物)并菌落PCR及基因测序验证。La1基因片段是通过公司合成(安徽通用生物)并亚克隆到pET28a质粒上。最后以La1与gshB基因为模板,利用表2突变引物(常规的PCR扩增实现)构建多位点突变酶基因GHS与HKS。将上述构建到pET-28a载体上的GHS,HKS,PPK以及ADK质粒转入E.coli BL21(DE3)(购于安徽通用生物)菌株里,在37℃、5ml含50uM卡那霉素(Kanamycin)的LB培养液中进行小量培养,当细胞生长至OD0.5-0.8加入0.5mM异丙基-β-D-硫代吡喃半乳糖苷(IPTG),37℃诱导蛋白表达3小时,最后收集细胞、冻融法进行细胞破碎、高速离心,收集到的上清液再利用十二烷基磺酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)确认蛋白表达。蛋白表达正确的菌株逐级培养至5升发酵罐,在1.0mM IPTG条件下37℃诱导表达4小时,收集湿细胞近35-55克;最后将细胞与适量的Tris.HCl缓冲液(25mM,pH=8.0)混合均匀后用高压破碎仪低温破碎,高速离心除去细胞壁后酶液保存在4℃冰箱备用。LB培养基构成为:1%胰蛋白胨、0.5%酵母粉,1%NaCl,1%磷酸氢二钾、1%磷酸氢二钾以及5%的甘油。
在1L 100mM pH 8.0的三羟甲基氨基甲烷盐酸(Tris.HCl)溶液中分别加入15克甘氨酸(200mM),31克L-组氨酸(200mM),29.2克L-赖氨酸(200mM),5.6克三磷酸腺苷二钠盐ATP(10mM),1.8克氯化镁(20mM),3.75克氯化钾(20mM)以及51.6克多聚磷酸(Sigma,25聚,500mM单磷酸),待pH值调节到8.0后;加入1000U的GHS酶液,1500U的HKS酶液,2000U的PPK以及1200U的ADK酶液。该反应体系在室温缓慢搅拌6小时(反应过程中通过添加HCl或NaOH水溶液维持体系pH值在6.5-9.0)后检测原料大部分消耗(利用ProFoldin公司L-组氨酸检测试剂盒检测反应液中残留的组氨酸原料)。最后通过调节反应液pH终止反应并沉底反应液中的蛋白(加酸调节溶液pH值到1.5后并快速搅拌),过滤除去蛋白沉淀,随后将溶液调回pH值7.0;利用反渗透除盐,D201阴离子交换树酯除含磷酸杂质(用去离子水做洗脱液,三胜肽GHK由于与树脂结合能力弱直接流出),冻干后甘氨酸-L-组氨酸-L-赖氨酸粗品通过纯水和乙醇1:(1-3)v/v结晶得到59克灰白色固体(收率87%,纯度96.0%)。纯化后三胜肽在600MVarian在D2O溶液核磁谱图见图3,上图为1H-NMR,下图为13C-NMR。
实施例2:催化制备三胜肽(GHKS-1,PPK,ADK组合)
三胜肽GHK合成酶基因片段GHKS-1是通过基因公司合成(安徽通用生物),并亚克隆到pET28a质粒上;与实施例1相同,该质粒转入E coli BL21(DE3)菌株进行小量蛋白表达后放大到5L发酵罐内发酵生产,收集到的湿细胞约为40克;而实施例1制备的多聚磷酸激酶PPK与腺苷酸激酶ADK酶液则直接用于后续制备反应。
反应条件与实施例1类似,在1L 100mM pH 8.0的三羟甲基氨基甲烷盐酸溶液中分别加入11.2克甘氨酸(150mM),23.2克L-组氨酸(150mM),21.9克L-赖氨酸(150mM),5.6克三磷酸腺苷二钠盐ATP(10mM),1.8克氯化镁(20mM),3.75克氯化钾(20mM)以及20.6克多聚磷酸(200mM单磷酸);pH调节到8.0后加入2000U的GHKS-1酶液,1500U的PPK以及1000U的ADK酶液。室温反应10个小时后监测到反应液中L-组氨酸消耗完全,最后通过在反应液中加入HCl溶液至pH 1.5终止反应并沉淀蛋白,过滤除去蛋白沉淀,清液pH值调回7.0后反渗透法除盐,最后用阴离子交换柱除溶液中含磷酸杂质,流出液浓缩后用乙醇与水结晶纯化得31.6克三胜肽纯品(收率62%,纯度91.2%)。纯化后三胜肽在600M Varian在D2O溶液核磁谱图同实施例1。
实施例3:催化制备三胜肽(GHKS-1,PPK,ADK组合)
与实施例2类似,三胜肽合成酶基因片段GHKS-2通过基因公司合成(安徽通用生物),并亚克隆到pET28a质粒上;蛋白小量表达验证后直接放大制备,过表达细胞破碎液保存在4℃冻存备用;实施例1制备的多聚磷酸激酶PPK与腺苷酸激酶ADK酶液可直接用于此次酶反应。
反应与实施例2类似,往1L 100mM pH 8.0的三羟甲基氨基甲烷盐酸溶液中分别加入15克甘氨酸(200mM),31克L-组氨酸(200mM),29.2克L-赖氨酸(200mM),5.6克三磷酸腺苷二钠盐ATP(10mM),1.8克氯化镁(20mM),3.75克氯化钾(20mM)以及51.6克多聚磷酸(500mM单磷酸);待pH值调节到8.0后加入2000U的GHKS-2酶液,2000U的PPK以及1500U的ADK酶液,反应体系室温搅拌7小时(维持反应体系pH值在6.5-9.0)后监测发现大部分组氨酸原料转化完全。加HCl水溶液终止反应并变性沉淀蛋白,与上相同,最后除盐并用阴离子交换柱除去反应中的含磷酸杂质,三胜肽粗液浓缩后结晶,最终得到61.8克灰白色固体(收率91%,纯度94.5%)。纯化后三胜肽在600M Varian在D2O溶液核磁谱图同实施例1。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 深圳瑞德林生物技术有限公司
<120> 一种突变酶及其应用和酶催化法制备三胜肽的工艺
<130> S20P1906
<160> 18
<170> SIPOSequenceListing 1.0
<210> 1
<211> 419
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Met Thr Gln Ala Lys Glu Asn Ile Leu Val Val Val Asp Gly Tyr Ser
1 5 10 15
Ser Gly Ser Gln Leu Pro Thr Leu Met Ala Glu Ser Gly Trp Lys Cys
20 25 30
Val His Val Ser Ser Ser Ala Asn Pro Pro Glu Tyr Tyr Leu Arg Thr
35 40 45
Tyr His Lys Asp Glu Tyr Ile Ala His Phe Glu Tyr Gln Gly Asp Ile
50 55 60
Gln Ser Leu Ala Ser Ala Val Glu Ala Trp His Pro Ala Ala Val Leu
65 70 75 80
Pro Gly Thr Glu Ser Gly Val Ile Val Ala Asp Leu Leu Ala Ala Ala
85 90 95
Leu Gln Leu Pro Gly Asn Asp Pro Ser Thr Ser Leu Ala Arg Arg Asp
100 105 110
Lys Tyr Thr Met His Glu Ser Leu Lys Ala Val Gly Leu Arg Ser Met
115 120 125
Asp His Phe Leu Ala Val Asp Arg Asp Ala Leu Ser Ala Trp Ala Glu
130 135 140
Arg Gly Ser Trp Pro Val Val Ile Lys Pro Gln Ala Ser Ala Gly Thr
145 150 155 160
Asp Ser Val Thr Phe Cys Ala Asp Gln Gly Glu Leu Leu Glu Ser Phe
165 170 175
Asp Gln Leu Phe Gly Thr Val Asn Gln Leu Gly Glu Arg Asn Asn Ala
180 185 190
Val Leu Ala Gln Arg Leu Leu Val Gly Pro Glu Tyr Phe Ile Asn Gly
195 200 205
Val Ser Gly His Gly Lys His Leu Ile Thr Glu Ile Trp Arg Ala Asp
210 215 220
Lys Leu Pro Ala Pro Asp Gly Gly Trp Ile Tyr Asp Arg Ala Val Leu
225 230 235 240
Phe Asp Pro Thr Ser Pro Glu Met Gln Glu Ile Val Arg Tyr Val His
245 250 255
Gly Val Leu Asp Ala Leu Gly Ile Arg Tyr Gly Ala Asn His Thr Glu
260 265 270
Leu Ile Val Thr Ala Asp Gly Pro Thr Leu Ile Glu Cys Ala Ser Arg
275 280 285
Leu Ser Gly Gly Leu His Arg Pro Ala Ala Asn Tyr Ala Val Gly Ala
290 295 300
Ser Gln Leu Asp Leu Val Gly Lys Leu Val Arg Glu Gly Glu Ser Ala
305 310 315 320
Ile Asp Asp Ile Leu Gln Thr Trp Gln Pro His Arg Tyr Ala Leu Trp
325 330 335
Gln Val Gln Phe Ile Ser Asn Gln Glu Gly Val Val Ala Arg Ser Ser
340 345 350
Tyr Asp Glu Leu Leu Lys Thr Leu Lys Ser Asn Ala Trp Leu Gln Arg
355 360 365
Ala Pro Lys Glu Gly Asp Thr Val Val Lys Thr Val Asp Leu Phe Ser
370 375 380
Ser Pro Gly Ile Val Phe Met Ser His Ala Asp Gly Asn Val Leu His
385 390 395 400
Asp Asp Tyr Arg Thr Val Arg Glu Trp Glu Arg Thr Ser Arg Leu Phe
405 410 415
Ser Val Gln
<210> 2
<211> 419
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Met Thr Gln Ala Lys Glu Asn Ile Leu Val Val Val Asp Gly Tyr Ser
1 5 10 15
Ser Gly Ser Gln Leu Pro Thr Leu Met Ala Glu Ser Gly Trp Lys Cys
20 25 30
Val His Val Ser Ser Ser Ala Asn Pro Pro Glu Tyr Tyr Leu Arg Thr
35 40 45
Tyr His Lys Asp Glu Tyr Ile Ala His Phe Glu Tyr Gln Gly Asp Ile
50 55 60
Gln Ser Leu Ala Ser Ala Val Glu Ala Trp His Pro Ala Ala Val Leu
65 70 75 80
Pro Gly Thr Lys Ser Gly Val Ile Val Ala Asp Leu Leu Ala Ala Ala
85 90 95
Leu Gln Leu Pro Gly Asn Asp Pro Ser Thr Ser Leu Ala Arg Arg Asp
100 105 110
Lys Tyr Thr Met His Glu Ser Leu Lys Ala Val Gly Leu Arg Ser Met
115 120 125
Asp His Phe Leu Ala Val Asp Arg Asp Ala Leu Ser Ala Trp Ala Glu
130 135 140
Arg Gly Ser Trp Pro Val Val Ile Lys Pro Gln Ala Ser His Asp Thr
145 150 155 160
Asp Ser Val Thr Phe Cys Ala Asp Gln Gly Glu Leu Leu Glu Ser Phe
165 170 175
Asp Gln Leu Phe Gly Thr Val Asn Gln Leu Gly Glu Arg Asn Asn Ala
180 185 190
Val Leu Ala Gln Arg Leu Leu Val Gly Pro Glu Tyr Phe Ile Asn Gly
195 200 205
Val Ser Gly His Gly Lys His Leu Ile Thr Glu Ile Trp Arg Ala Asp
210 215 220
Lys Leu Pro Ala Pro Asp Gly Gly Trp Ile Tyr Asp Arg Ala Val Leu
225 230 235 240
Phe Asp Pro Ile Ser Pro Glu Met Gln Glu Ile Val Arg Tyr Val His
245 250 255
Gly Val Leu Asp Ala Leu Gly Ile Arg Tyr Gly Ala Asn His Thr Glu
260 265 270
Leu Ile Val Thr Ala Asp Gly Pro Thr Leu Ile Glu Cys Ala Ser Arg
275 280 285
Leu Leu Gly Trp Leu His Arg Pro Ala Ala Asn Tyr Ala Val Gly Ala
290 295 300
Ser Gln Leu Asp Leu Val Gly Lys Leu Val Arg Glu Gly Glu Ser Ala
305 310 315 320
Ile Asp Asp Ile Leu Gln Thr Trp Gln Pro His Arg Tyr Ala Leu Trp
325 330 335
Gln Val Gln Phe Ile Ser Asn Gln Glu Gly Val Val Ala Arg Ser Ser
340 345 350
Tyr Asp Glu Leu Leu Lys Thr Leu Lys Ser Asn Ala Trp Leu Gln Arg
355 360 365
Ala Pro Lys Glu Gly Asp Thr Val Val Lys Thr Val Asp Leu Phe Ser
370 375 380
Ser Pro Gly Ile Val Phe Met Ser His Ala Asp Gly Asn Val Leu His
385 390 395 400
Asp Asp Tyr Arg Thr Val Arg Glu Trp Glu Arg Thr Ser Arg Leu Phe
405 410 415
Ser Val Gln
<210> 3
<211> 491
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Met Ala His Tyr Pro Pro Ser Lys Asp Gln Leu Asn Glu Leu Ile Gln
1 5 10 15
Glu Val Asn Gln Trp Ala Ile Thr Asn Gly Leu Ser Met Tyr Pro Pro
20 25 30
Lys Phe Glu Glu Asn Pro Ser Asn Ala Ser Val Ser Pro Val Thr Ile
35 40 45
Tyr Pro Thr Pro Ile Pro Arg Lys Cys Phe Asp Glu Ala Val Gln Ile
50 55 60
Gln Pro Val Phe Asn Glu Leu Tyr Ala Arg Ile Thr Gln Asp Met Ala
65 70 75 80
Gln Pro Asp Ser Tyr Leu His Lys Thr Thr Glu Ala Leu Ala Leu Ser
85 90 95
Asp Ser Glu Phe Thr Gly Lys Leu Trp Ser Leu Tyr Leu Ala Thr Leu
100 105 110
Lys Ser Ala Gln Tyr Lys Lys Gln Asn Phe Arg Leu Gly Ile Phe Arg
115 120 125
Ser Asp Tyr Leu Ile Asp Lys Lys Lys Gly Thr Glu Gln Ile Lys Gln
130 135 140
Val Glu Phe Asn Thr Val Ser Val Ser Phe Ala Gly Leu Ser Glu Lys
145 150 155 160
Val Asp Arg Leu His Ser Tyr Leu Asn Arg Ala Asn Lys Tyr Asp Pro
165 170 175
Lys Gly Pro Ile Tyr Asn Asp Gln Asn Met Val Ile Ser Asp Ser Gly
180 185 190
Tyr Leu Leu Ser Lys Ala Leu Ala Lys Ala Val Glu Ser Tyr Lys Ser
195 200 205
Gln Gln Ser Ser Ser Thr Thr Ser Asp Pro Ile Val Ala Phe Ile Val
210 215 220
Gln Arg Asn Glu Arg Asn Val Phe Asp Gln Lys Val Leu Glu Leu Asn
225 230 235 240
Leu Leu Glu Lys Phe Gly Thr Lys Ser Val Arg Leu Thr Phe Asp Asp
245 250 255
Val Asn Asp Lys Leu Phe Ile Asp Asp Lys Thr Gly Lys Leu Phe Ile
260 265 270
Arg Asp Thr Glu Gln Glu Ile Ala Val Val Tyr Tyr Arg Thr Gly Tyr
275 280 285
Thr Thr Thr Asp Tyr Thr Ser Glu Lys Asp Trp Glu Ala Arg Leu Phe
290 295 300
Leu Glu Lys Ser Phe Ala Ile Lys Ala Pro Asp Leu Leu Thr Gln Leu
305 310 315 320
Ser Gly Ser Lys Lys Ile Gln Gln Leu Leu Thr Asp Glu Gly Val Leu
325 330 335
Gly Lys Tyr Ile Ser Asp Ala Glu Lys Lys Ser Ser Leu Leu Lys Thr
340 345 350
Phe Val Lys Ile Tyr Pro Leu Asp Asp Thr Lys Leu Gly Arg Glu Gly
355 360 365
Lys Arg Leu Ala Leu Ser Glu Pro Ser Lys Tyr Val Leu Lys Pro Gln
370 375 380
Arg Glu Gly Gly Gly Asn Asn Val Tyr Lys Glu Asn Ile Pro Asn Phe
385 390 395 400
Leu Lys Gly Ile Glu Glu Arg His Trp Asp Ala Tyr Ile Leu Met Glu
405 410 415
Leu Ile Glu Pro Glu Leu Asn Glu Asn Asn Ile Ile Leu Arg Asp Asn
420 425 430
Lys Ser Tyr Asn Glu Pro Ile Ile Ser Glu Leu Gly Ile Tyr Gly Cys
435 440 445
Val Leu Phe Asn Asp Glu Gln Val Leu Ser Asn Glu Phe Ser Gly Ser
450 455 460
Leu Leu Arg Ser Lys Phe Asn Thr Ser Asn Glu Gly Gly Val Ala Ala
465 470 475 480
Gly Phe Gly Cys Leu Asp Ser Ile Ile Leu Tyr
485 490
<210> 4
<211> 491
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Met Ala His Tyr Pro Pro Ser Lys Asp Gln Leu Asn Glu Leu Ile Gln
1 5 10 15
Glu Val Asn Gln Trp Ala Ile Thr Asn Gly Leu Ser Met Tyr Pro Pro
20 25 30
Lys Phe Glu Glu Asn Pro Ser Asn Ala Ser Val Ser Pro Val Thr Ile
35 40 45
Tyr Pro Thr Pro Ile Pro Arg Lys Cys Phe Asp Glu Ala Val Gln Ile
50 55 60
Gln Pro Val Phe Asn Glu Leu Tyr Ala Arg Ile Thr Gln Asp Met Ala
65 70 75 80
Gln Pro Asp Ser Tyr Leu His Lys Thr Thr Glu Ala Leu Ala Leu Ser
85 90 95
Asp Ser Glu Phe Thr Gly Lys Leu Trp Ser Leu Tyr Leu Ala Thr Leu
100 105 110
Lys Ser Ala Gln Tyr Lys Lys Gln Asn Phe Arg Leu Gly Ile Phe Arg
115 120 125
Ser Gln Tyr Leu Ile Asp Lys Lys Lys Gly Thr Glu Gln Ile Lys Gln
130 135 140
Val Leu Phe Ser Thr Phe Ser Val Glu Phe Ala Gly Leu Ser Glu Lys
145 150 155 160
Val Asp Arg Leu His Ser Tyr Leu Asn Arg Ala Asn Lys Tyr Asp Pro
165 170 175
Lys Gly Pro Ile Tyr Asn Asp Gln Asn Met Val Ile Ser Asp Ser Gly
180 185 190
Tyr Leu Leu Ser Lys Ala Leu Ala Lys Ala Val Glu Ser Tyr Lys Ser
195 200 205
Gln Gln Ser Ser Ser Thr Thr Ser Asp Pro Ile Val Ala Phe Ile Val
210 215 220
Gln Arg Asn Ile Arg His Val Phe Thr Gln Lys Val Leu Glu Leu Asn
225 230 235 240
Leu Leu Glu Lys Phe Gly Thr Lys Ser Val Arg Leu Thr Phe Asp Asp
245 250 255
Val Asn Asp Lys Leu Phe Ile Asp Asp Lys Thr Gly Lys Leu Phe Ile
260 265 270
Arg Asp Thr Glu Gln Glu Ile Ala Val Val Tyr Tyr Val Thr Gly Tyr
275 280 285
Thr Thr Thr Asp Tyr Thr Ser Glu Lys Asp Trp Glu Ala Arg Leu Phe
290 295 300
Leu Glu Lys Ser Phe Ala Ile Lys Ala Pro Asp Leu Leu Thr Gln Leu
305 310 315 320
Ser Gly Ser Lys Lys Ile Gln Gln Leu Leu Thr Asp Glu Gly Val Leu
325 330 335
Gly Lys Tyr Ile Ser Asp Ala Glu Lys Lys Ser Ser Leu Leu Lys Thr
340 345 350
Phe Val Lys Ile Tyr Pro Leu Asp Asp Thr Lys Leu Gly Arg Glu Gly
355 360 365
Lys Arg Leu Ala Leu Ser Glu Pro Ser Lys Tyr Val Leu Lys Pro Gln
370 375 380
Arg Glu Asn Gly Gly Asn Asn Val Tyr Lys Glu Asn Ile Pro Asn Phe
385 390 395 400
Leu Lys Gly Ile Glu Glu Arg His Trp Asp Ala Tyr Ile Leu Met Glu
405 410 415
Leu Ile Glu Pro Glu Leu Asn Glu Asn Asn Ile Ile Leu Arg Asp Asn
420 425 430
Lys Ser Tyr Asn Glu Pro Ile Ile Ser Glu Leu Gly Asp Tyr Gly Cys
435 440 445
Val Leu Phe Asn Asp Glu Gln Val Leu Ser Asn Glu Phe Ser Gly Ser
450 455 460
Leu Leu Arg Ser Lys Phe Asn Thr Ser Asn Glu Gly Gly Val Ala Ala
465 470 475 480
Gly Phe Gly Cys Leu Asp Ser Ile Ile Leu Tyr
485 490
<210> 5
<211> 930
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Met Thr Gln Ala Lys Glu Asn Ile Leu Val Val Val Asp Gly Tyr Ser
1 5 10 15
Ser Gly Ser Gln Leu Pro Thr Leu Met Ala Glu Ser Gly Trp Lys Cys
20 25 30
Val His Val Ser Ser Ser Ala Asn Pro Pro Glu Tyr Tyr Leu Arg Thr
35 40 45
Tyr His Lys Asp Glu Tyr Ile Ala His Phe Glu Tyr Gln Gly Asp Ile
50 55 60
Gln Ser Leu Ala Ser Ala Val Glu Ala Trp His Pro Ala Ala Val Leu
65 70 75 80
Pro Gly Thr Lys Ser Gly Val Ile Val Ala Asp Leu Leu Ala Ala Ala
85 90 95
Leu Gln Leu Pro Gly Asn Asp Pro Ser Thr Ser Leu Ala Arg Arg Asp
100 105 110
Lys Tyr Thr Met His Glu Ser Leu Lys Ala Val Gly Leu Arg Ser Met
115 120 125
Asp His Phe Leu Ala Val Asp Arg Asp Ala Leu Ser Ala Trp Ala Glu
130 135 140
Arg Gly Ser Trp Pro Val Val Ile Lys Pro Gln Ala Ser His Asp Thr
145 150 155 160
Asp Ser Val Thr Phe Cys Ala Asp Gln Gly Glu Leu Leu Glu Ser Phe
165 170 175
Asp Gln Leu Phe Gly Thr Val Asn Gln Leu Gly Glu Arg Asn Asn Ala
180 185 190
Val Leu Ala Gln Arg Leu Leu Val Gly Pro Glu Tyr Phe Ile Asn Gly
195 200 205
Val Ser Gly His Gly Lys His Leu Ile Thr Glu Ile Trp Arg Ala Asp
210 215 220
Lys Leu Pro Ala Pro Asp Gly Gly Trp Ile Tyr Asp Arg Ala Val Leu
225 230 235 240
Phe Asp Pro Ile Ser Pro Glu Met Gln Glu Ile Val Arg Tyr Val His
245 250 255
Gly Val Leu Asp Ala Leu Gly Ile Arg Tyr Gly Ala Asn His Thr Glu
260 265 270
Leu Ile Val Thr Ala Asp Gly Pro Thr Leu Ile Glu Cys Ala Ser Arg
275 280 285
Leu Leu Gly Trp Leu His Arg Pro Ala Ala Asn Tyr Ala Val Gly Ala
290 295 300
Ser Gln Leu Asp Leu Val Gly Lys Leu Val Arg Glu Gly Glu Ser Ala
305 310 315 320
Ile Asp Asp Ile Leu Gln Thr Trp Gln Pro His Arg Tyr Ala Leu Trp
325 330 335
Gln Val Gln Phe Ile Ser Asn Gln Glu Gly Val Val Ala Arg Ser Ser
340 345 350
Tyr Asp Glu Leu Leu Lys Thr Leu Lys Ser Asn Ala Trp Leu Gln Arg
355 360 365
Ala Pro Lys Glu Gly Asp Thr Val Val Lys Thr Val Asp Leu Phe Ser
370 375 380
Ser Pro Gly Ile Val Phe Met Ser His Ala Asp Gly Asn Val Leu His
385 390 395 400
Asp Asp Tyr Arg Thr Val Arg Glu Trp Glu Arg Thr Ser Arg Leu Phe
405 410 415
Ser Val Gln Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
420 425 430
Gly Ser Gly Gly Gly Gly Ser Met Ala His Tyr Pro Pro Ser Lys Asp
435 440 445
Gln Leu Asn Glu Leu Ile Gln Glu Val Asn Gln Trp Ala Ile Thr Asn
450 455 460
Gly Leu Ser Met Tyr Pro Pro Lys Phe Glu Glu Asn Pro Ser Asn Ala
465 470 475 480
Ser Val Ser Pro Val Thr Ile Tyr Pro Thr Pro Ile Pro Arg Lys Cys
485 490 495
Phe Asp Glu Ala Val Gln Ile Gln Pro Val Phe Asn Glu Leu Tyr Ala
500 505 510
Arg Ile Thr Gln Asp Met Ala Gln Pro Asp Ser Tyr Leu His Lys Thr
515 520 525
Thr Glu Ala Leu Ala Leu Ser Asp Ser Glu Phe Thr Gly Lys Leu Trp
530 535 540
Ser Leu Tyr Leu Ala Thr Leu Lys Ser Ala Gln Tyr Lys Lys Gln Asn
545 550 555 560
Phe Arg Leu Gly Ile Phe Arg Ser Gln Tyr Leu Ile Asp Lys Lys Lys
565 570 575
Gly Thr Glu Gln Ile Lys Gln Val Leu Phe Ser Thr Phe Ser Val Glu
580 585 590
Phe Ala Gly Leu Ser Glu Lys Val Asp Arg Leu His Ser Tyr Leu Asn
595 600 605
Arg Ala Asn Lys Tyr Asp Pro Lys Gly Pro Ile Tyr Asn Asp Gln Asn
610 615 620
Met Val Ile Ser Asp Ser Gly Tyr Leu Leu Ser Lys Ala Leu Ala Lys
625 630 635 640
Ala Val Glu Ser Tyr Lys Ser Gln Gln Ser Ser Ser Thr Thr Ser Asp
645 650 655
Pro Ile Val Ala Phe Ile Val Gln Arg Asn Ile Arg His Val Phe Thr
660 665 670
Gln Lys Val Leu Glu Leu Asn Leu Leu Glu Lys Phe Gly Thr Lys Ser
675 680 685
Val Arg Leu Thr Phe Asp Asp Val Asn Asp Lys Leu Phe Ile Asp Asp
690 695 700
Lys Thr Gly Lys Leu Phe Ile Arg Asp Thr Glu Gln Glu Ile Ala Val
705 710 715 720
Val Tyr Tyr Val Thr Gly Tyr Thr Thr Thr Asp Tyr Thr Ser Glu Lys
725 730 735
Asp Trp Glu Ala Arg Leu Phe Leu Glu Lys Ser Phe Ala Ile Lys Ala
740 745 750
Pro Asp Leu Leu Thr Gln Leu Ser Gly Ser Lys Lys Ile Gln Gln Leu
755 760 765
Leu Thr Asp Glu Gly Val Leu Gly Lys Tyr Ile Ser Asp Ala Glu Lys
770 775 780
Lys Ser Ser Leu Leu Lys Thr Phe Val Lys Ile Tyr Pro Leu Asp Asp
785 790 795 800
Thr Lys Leu Gly Arg Glu Gly Lys Arg Leu Ala Leu Ser Glu Pro Ser
805 810 815
Lys Tyr Val Leu Lys Pro Gln Arg Glu Asn Gly Gly Asn Asn Val Tyr
820 825 830
Lys Glu Asn Ile Pro Asn Phe Leu Lys Gly Ile Glu Glu Arg His Trp
835 840 845
Asp Ala Tyr Ile Leu Met Glu Leu Ile Glu Pro Glu Leu Asn Glu Asn
850 855 860
Asn Ile Ile Leu Arg Asp Asn Lys Ser Tyr Asn Glu Pro Ile Ile Ser
865 870 875 880
Glu Leu Gly Asp Tyr Gly Cys Val Leu Phe Asn Asp Glu Gln Val Leu
885 890 895
Ser Asn Glu Phe Ser Gly Ser Leu Leu Arg Ser Lys Phe Asn Thr Ser
900 905 910
Asn Glu Gly Gly Val Ala Ala Gly Phe Gly Cys Leu Asp Ser Ile Ile
915 920 925
Leu Tyr
930
<210> 6
<211> 930
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Met Thr Gln Ala Lys Glu Asn Ile Leu Val Val Val Asp Gly Tyr Ser
1 5 10 15
Ser Gly Ser Gln Leu Pro Thr Leu Met Ala Glu Ser Gly Trp Lys Cys
20 25 30
Val His Val Ser Ser Ser Ala Asn Pro Pro Glu Tyr Tyr Leu Arg Thr
35 40 45
Tyr His Lys Asp Glu Tyr Ile Ala His Phe Glu Tyr Gln Gly Asp Ile
50 55 60
Gln Ser Leu Ala Ser Ala Val Glu Ala Trp His Pro Ala Ala Val Leu
65 70 75 80
Pro Gly Thr Lys Ser Gly Val Ile Val Ala Asp Leu Leu Ala Ala Ala
85 90 95
Leu Gln Leu Pro Gly Asn Asp Pro Ser Thr Ser Leu Ala Arg Arg Asp
100 105 110
Lys Tyr Thr Met His Glu Ser Leu Lys Ala Val Gly Leu Arg Ser Met
115 120 125
Asp His Phe Leu Ala Val Asp Arg Asp Ala Leu Ser Ala Trp Ala Glu
130 135 140
Arg Gly Ser Trp Pro Val Val Ile Lys Pro Gln Ala Ser His Asp Thr
145 150 155 160
Asp Ser Val Thr Phe Cys Ala Asp Gln Gly Glu Leu Leu Glu Ser Phe
165 170 175
Asp Gln Leu Phe Gly Thr Val Asn Gln Leu Gly Glu Arg Asn Asn Ala
180 185 190
Val Leu Ala Gln Arg Leu Leu Val Gly Pro Glu Tyr Phe Ile Asn Gly
195 200 205
Val Ser Gly His Gly Lys His Leu Ile Thr Glu Ile Trp Arg Ala Asp
210 215 220
Lys Leu Pro Ala Pro Asp Gly Gly Trp Ile Tyr Asp Arg Ala Val Leu
225 230 235 240
Phe Asp Pro Ile Ser Pro Glu Met Gln Glu Ile Val Arg Tyr Val His
245 250 255
Gly Val Leu Asp Ala Leu Gly Ile Arg Tyr Gly Ala Asn His Thr Glu
260 265 270
Leu Ile Val Thr Ala Asp Gly Pro Thr Leu Ile Glu Cys Ala Ser Arg
275 280 285
Leu Leu Gly Trp Leu His Arg Pro Ala Ala Asn Tyr Ala Val Gly Ala
290 295 300
Ser Gln Leu Asp Leu Val Gly Lys Leu Val Arg Glu Gly Glu Ser Ala
305 310 315 320
Ile Asp Asp Ile Leu Gln Thr Trp Gln Pro His Arg Tyr Ala Leu Trp
325 330 335
Gln Val Gln Phe Ile Ser Asn Gln Glu Gly Val Val Ala Arg Ser Ser
340 345 350
Tyr Asp Glu Leu Leu Lys Thr Leu Lys Ser Asn Ala Trp Leu Gln Arg
355 360 365
Ala Pro Lys Glu Gly Asp Thr Val Val Lys Thr Val Asp Leu Phe Ser
370 375 380
Ser Pro Gly Ile Val Phe Met Ser His Ala Asp Gly Asn Val Leu His
385 390 395 400
Asp Asp Tyr Arg Thr Val Arg Glu Trp Glu Arg Thr Ser Arg Leu Phe
405 410 415
Ser Val Gln Gly Gly Gly Gly Ser Glu Ala Ala Ala Lys Glu Ala Ala
420 425 430
Ala Lys Gly Gly Gly Gly Ser Met Ala His Tyr Pro Pro Ser Lys Asp
435 440 445
Gln Leu Asn Glu Leu Ile Gln Glu Val Asn Gln Trp Ala Ile Thr Asn
450 455 460
Gly Leu Ser Met Tyr Pro Pro Lys Phe Glu Glu Asn Pro Ser Asn Ala
465 470 475 480
Ser Val Ser Pro Val Thr Ile Tyr Pro Thr Pro Ile Pro Arg Lys Cys
485 490 495
Phe Asp Glu Ala Val Gln Ile Gln Pro Val Phe Asn Glu Leu Tyr Ala
500 505 510
Arg Ile Thr Gln Asp Met Ala Gln Pro Asp Ser Tyr Leu His Lys Thr
515 520 525
Thr Glu Ala Leu Ala Leu Ser Asp Ser Glu Phe Thr Gly Lys Leu Trp
530 535 540
Ser Leu Tyr Leu Ala Thr Leu Lys Ser Ala Gln Tyr Lys Lys Gln Asn
545 550 555 560
Phe Arg Leu Gly Ile Phe Arg Ser Gln Tyr Leu Ile Asp Lys Lys Lys
565 570 575
Gly Thr Glu Gln Ile Lys Gln Val Leu Phe Ser Thr Phe Ser Val Glu
580 585 590
Phe Ala Gly Leu Ser Glu Lys Val Asp Arg Leu His Ser Tyr Leu Asn
595 600 605
Arg Ala Asn Lys Tyr Asp Pro Lys Gly Pro Ile Tyr Asn Asp Gln Asn
610 615 620
Met Val Ile Ser Asp Ser Gly Tyr Leu Leu Ser Lys Ala Leu Ala Lys
625 630 635 640
Ala Val Glu Ser Tyr Lys Ser Gln Gln Ser Ser Ser Thr Thr Ser Asp
645 650 655
Pro Ile Val Ala Phe Ile Val Gln Arg Asn Ile Arg His Val Phe Thr
660 665 670
Gln Lys Val Leu Glu Leu Asn Leu Leu Glu Lys Phe Gly Thr Lys Ser
675 680 685
Val Arg Leu Thr Phe Asp Asp Val Asn Asp Lys Leu Phe Ile Asp Asp
690 695 700
Lys Thr Gly Lys Leu Phe Ile Arg Asp Thr Glu Gln Glu Ile Ala Val
705 710 715 720
Val Tyr Tyr Val Thr Gly Tyr Thr Thr Thr Asp Tyr Thr Ser Glu Lys
725 730 735
Asp Trp Glu Ala Arg Leu Phe Leu Glu Lys Ser Phe Ala Ile Lys Ala
740 745 750
Pro Asp Leu Leu Thr Gln Leu Ser Gly Ser Lys Lys Ile Gln Gln Leu
755 760 765
Leu Thr Asp Glu Gly Val Leu Gly Lys Tyr Ile Ser Asp Ala Glu Lys
770 775 780
Lys Ser Ser Leu Leu Lys Thr Phe Val Lys Ile Tyr Pro Leu Asp Asp
785 790 795 800
Thr Lys Leu Gly Arg Glu Gly Lys Arg Leu Ala Leu Ser Glu Pro Ser
805 810 815
Lys Tyr Val Leu Lys Pro Gln Arg Glu Asn Gly Gly Asn Asn Val Tyr
820 825 830
Lys Glu Asn Ile Pro Asn Phe Leu Lys Gly Ile Glu Glu Arg His Trp
835 840 845
Asp Ala Tyr Ile Leu Met Glu Leu Ile Glu Pro Glu Leu Asn Glu Asn
850 855 860
Asn Ile Ile Leu Arg Asp Asn Lys Ser Tyr Asn Glu Pro Ile Ile Ser
865 870 875 880
Glu Leu Gly Asp Tyr Gly Cys Val Leu Phe Asn Asp Glu Gln Val Leu
885 890 895
Ser Asn Glu Phe Ser Gly Ser Leu Leu Arg Ser Lys Phe Asn Thr Ser
900 905 910
Asn Glu Gly Gly Val Ala Ala Gly Phe Gly Cys Leu Asp Ser Ile Ile
915 920 925
Leu Tyr
930
<210> 7
<211> 286
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Met Pro Met Val Ala Ala Val Glu Phe Ala Lys Ser Pro Ala Glu Val
1 5 10 15
Leu Arg Val Gly Ser Gly Phe Ser Leu Ala Gly Val Asp Pro Glu Ser
20 25 30
Thr Pro Gly Tyr Thr Gly Val Lys Ala Asp Gly Lys Ala Leu Leu Ala
35 40 45
Ala Gln Asp Ala Arg Leu Ala Glu Leu Gln Glu Lys Leu Phe Ala Glu
50 55 60
Gly Lys Phe Gly Asn Pro Lys Arg Leu Leu Leu Ile Leu Gln Ala Met
65 70 75 80
Asp Thr Ala Gly Lys Gly Gly Ile Val Ser His Val Val Gly Ala Met
85 90 95
Asp Pro Gln Gly Val Gln Leu Thr Ala Phe Lys Ala Pro Thr Asp Glu
100 105 110
Glu Lys Ser His Asp Phe Leu Trp Arg Ile Glu Lys Gln Val Pro Ala
115 120 125
Ala Gly Met Val Gly Val Phe Asp Arg Ser Gln Tyr Glu Asp Val Leu
130 135 140
Ile His Arg Val His Gly Trp Ala Asp Ala Ala Glu Leu Glu Arg Arg
145 150 155 160
Tyr Ala Ala Ile Asn Asp Phe Glu Ser Arg Leu Thr Glu Gln Gly Thr
165 170 175
Thr Ile Val Lys Val Met Leu Asn Ile Ser Lys Asp Glu Gln Lys Lys
180 185 190
Arg Leu Ile Ala Arg Leu Asp Asp Pro Ser Lys His Trp Lys Tyr Ser
195 200 205
Arg Gly Asp Leu Ala Glu Arg Ala Tyr Trp Asp Asp Tyr Met Asp Ala
210 215 220
Tyr Ser Val Ala Phe Glu Lys Thr Ser Thr Glu Ile Ala Pro Trp His
225 230 235 240
Val Val Pro Ala Asn Lys Lys Trp Tyr Ala Arg Ile Ala Val Gln Gln
245 250 255
Leu Leu Leu Asp Ala Leu Gly Gly Leu Gln Leu Asp Trp Pro Lys Ala
260 265 270
Asp Phe Asp Val Ala Ala Glu Arg Ala Leu Val Val Glu Ser
275 280 285
<210> 8
<211> 214
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Met Arg Ile Ile Leu Leu Gly Ala Pro Gly Ala Gly Lys Gly Thr Gln
1 5 10 15
Ala Gln Phe Ile Met Glu Lys Tyr Gly Ile Pro Gln Ile Ser Thr Gly
20 25 30
Asp Met Leu Arg Ala Ala Val Lys Ser Gly Ser Glu Leu Gly Lys Gln
35 40 45
Ala Lys Asp Ile Met Asp Ala Gly Lys Leu Val Thr Asp Glu Leu Val
50 55 60
Ile Ala Leu Val Lys Glu Arg Ile Ala Gln Glu Asp Cys Arg Asn Gly
65 70 75 80
Phe Leu Leu Asp Gly Phe Pro Arg Thr Ile Pro Gln Ala Asp Ala Met
85 90 95
Lys Glu Ala Gly Ile Asn Val Asp Tyr Val Leu Glu Phe Asp Val Pro
100 105 110
Asp Glu Leu Ile Val Asp Arg Ile Val Gly Arg Arg Val His Ala Pro
115 120 125
Ser Gly Arg Val Tyr His Val Lys Phe Asn Pro Pro Lys Val Glu Gly
130 135 140
Lys Asp Asp Val Thr Gly Glu Glu Leu Thr Thr Arg Lys Asp Asp Gln
145 150 155 160
Glu Glu Thr Val Arg Lys Arg Leu Val Glu Tyr His Gln Met Thr Ala
165 170 175
Pro Leu Ile Gly Tyr Tyr Ser Lys Glu Ala Glu Ala Gly Asn Thr Lys
180 185 190
Tyr Ala Lys Val Asp Gly Thr Lys Pro Val Ala Glu Val Arg Ala Asp
195 200 205
Leu Glu Lys Ile Leu Gly
210
<210> 9
<211> 1260
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
atgacgcagg ccaaggaaaa catcttagtt gtggtcgatg gctactcctc aggcagtcag 60
ttgcctaccc tgatggcgga atccggctgg aagtgtgttc atgtctcgtc ctcggctaac 120
cccccggagt attacctgcg tacataccat aaggatgagt acatagctca ctttgagtat 180
caaggtgata tacagtcact tgctagtgct gttgaggcgt ggcatcccgc cgcagttctt 240
cctggtacgg aaagtggagt tattgtcgct gatttactgg cggctgcttt gcaattgcca 300
ggcaatgacc cgtcgacctc cctggcgaga cgcgacaaat atacgatgca tgagtcattg 360
aaagcggtgg gacttcggag tatggaccat ttccttgccg tcgatcgtga tgctttatca 420
gcttgggccg agcggggatc ttggccagtg gtaattaaac cccaggcttc ggcaggcaca 480
gacagtgtta cattctgcgc cgatcaggga gaattattag agtcgtttga tcaattgttc 540
ggcactgtga accaattggg tgaacgcaat aatgcagtgc tggctcagcg tctgttggtt 600
ggtcccgagt actttatcaa cggagtttct ggacatggca aacacctgat tacagagatt 660
tggcgtgcag acaagctgcc cgcaccggac gggggttgga tatacgaccg ggccgtgctg 720
tttgacccga cgagtcccga gatgcaggag attgtccgct acgtgcatgg agtattagat 780
gcccttggca tccgctatgg tgcgaaccat acagagctga tcgtaacggc tgatggccca 840
acactgatag aatgtgcctc ccgtttatcc gggggactgc atagacctgc agcgaactat 900
gcggttggcg catcacaact tgacttggtc ggtaaacttg tacgggaagg ggaaagcgct 960
atagatgata tactgcaaac ttggcaacct caccgctacg cattgtggca agtccaattc 1020
atatcgaatc aagagggagt agtggctcgg agttcgtacg acgaacttct taaaacgttg 1080
aaatccaatg cctggttgca acgggctccg aaggaaggcg ataccgtagt caagacagtc 1140
gacctgttca gctcgcccgg aatagtcttt atgtcacacg cagacggtaa tgttctgcac 1200
gacgattatc ggacggtccg ggaatgggag cgtacctcgc gcctgttctc ggtgcagtaa 1260
<210> 10
<211> 1260
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
atgacgcagg ccaaggaaaa catcttagtt gtggtcgatg gctactcctc aggcagtcag 60
ttgcctaccc tgatggcgga atccggctgg aagtgtgttc atgtctcgtc ctcggctaac 120
cccccggagt attacctgcg tacataccat aaggatgagt acatagctca ctttgagtat 180
caaggtgata tacagtcact tgctagtgct gttgaggcgt ggcatcccgc cgcagttctt 240
cctggtacga aaagtggagt tattgtcgct gatttactgg cggctgcttt gcaattgcca 300
ggcaatgacc cgtcgacctc cctggcgaga cgcgacaaat atacgatgca tgagtcattg 360
aaagcggtgg gacttcggag tatggaccat ttccttgccg tcgatcgtga tgctttatca 420
gcttgggccg agcggggatc ttggccagtg gtaattaaac cccaggcttc gcacgacaca 480
gacagtgtta cattctgcgc cgatcaggga gaattattag agtcgtttga tcaattgttc 540
ggcactgtga accaattggg tgaacgcaat aatgcagtgc tggctcagcg tctgttggtt 600
ggtcccgagt actttatcaa cggagtttct ggacatggca aacacctgat tacagagatt 660
tggcgtgcag acaagctgcc cgcaccggac gggggttgga tatacgaccg ggccgtgctg 720
tttgacccga tcagtcccga gatgcaggag attgtccgct acgtgcatgg agtattagat 780
gcccttggca tccgctatgg tgcgaaccat acagagctga tcgtaacggc tgatggccca 840
acactgatag aatgtgcctc ccgtttactc gggtggctgc atagacctgc agcgaactat 900
gcggttggcg catcacaact tgacttggtc ggtaaacttg tacgggaagg ggaaagcgct 960
atagatgata tactgcaaac ttggcaacct caccgctacg cattgtggca agtccaattc 1020
atatcgaatc aagagggagt agtggctcgg agttcgtacg acgaacttct taaaacgttg 1080
aaatccaatg cctggttgca acgggctccg aaggaaggcg ataccgtagt caagacagtc 1140
gacctgttca gctcgcccgg aatagtcttt atgtcacacg cagacggtaa tgttctgcac 1200
gacgattatc ggacggtccg ggaatgggag cgtacctcgc gcctgttctc ggtgcagtaa 1260
<210> 11
<211> 1476
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
atggcacact atccaccttc caaggatcaa ttgaatgaat tgatccagga agttaaccaa 60
tgggctatca ctaatggatt atccatgtat cctcctaaat tcgaggagaa cccatcaaat 120
gcatcggtgt caccagtaac tatctatcca accccaattc ctaggaaatg ttttgatgag 180
gccgttcaaa tacaaccggt attcaatgaa ttatacgccc gtattaccca agatatggcc 240
caacctgatt cttatttaca taaaacaact gaagcgttag ctctatcaga ttccgagttt 300
actggaaaac tgtggtctct ataccttgct accttaaaat ctgcacagta caaaaagcag 360
aattttaggc taggtatatt tagatcagat tatttgattg ataagaaaaa gggtactgaa 420
cagattaagc aagtcgagtt taatacagtg tcagtgtcat ttgcaggcct tagcgagaaa 480
gttgatagat tgcactctta tttaaatagg gcaaacaagt acgatcctaa aggaccaatt 540
tataatgatc aaaatatggt catttctgat tcaggatacc ttttgtctaa ggcattggcc 600
aaagctgtgg aatcgtataa gtcacaacaa agttcttcta caactagtga tcctattgtc 660
gcattcattg tgcaaagaaa cgagagaaat gtgtttgatc aaaaggtctt ggaattgaat 720
ctgttggaaa aattcggtac caaatctgtt aggttgacgt ttgatgatgt taacgataaa 780
ttgttcattg atgataaaac gggaaagctt ttcattaggg acacagagca ggaaatagcg 840
gtggtttatt acagaacggg ttacacaacc actgattaca cgtccgaaaa ggactgggag 900
gcaagactat tcctcgaaaa aagtttcgca ataaaggccc cagatttact cactcaatta 960
tctggctcca agaaaattca gcaattgttg acagatgagg gcgtattagg taaatacatc 1020
tccgatgctg agaaaaagag tagtttgtta aaaacttttg tcaaaatata tcccttggat 1080
gatacgaagc ttggcaggga aggcaagagg ctggcattaa gtgagccctc taaatacgtg 1140
ttaaaaccac agcgggaagg tggcggaaac aatgtttata aagaaaatat tcctaatttt 1200
ttgaaaggta tcgaagaacg tcactgggat gcatatattc tcatggagtt gattgaacca 1260
gagttgaatg aaaataatat tatattacgt gataacaaat cttacaacga accaatcatc 1320
agtgaactag gaatttatgg ttgcgttcta tttaacgacg agcaagtttt atcgaacgaa 1380
tttagtggct cattactaag atccaaattt aatacttcaa atgaaggtgg agtggcggca 1440
ggattcggat gtttggacag tattattctt tactag 1476
<210> 12
<211> 1476
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 12
atggcacact atccaccttc caaggatcaa ttgaatgaat tgatccagga agttaaccaa 60
tgggctatca ctaatggatt atccatgtat cctcctaaat tcgaggagaa cccatcaaat 120
gcatcggtgt caccagtaac tatctatcca accccaattc ctaggaaatg ttttgatgag 180
gccgttcaaa tacaaccggt attcaatgaa ttatacgccc gtattaccca agatatggcc 240
caacctgatt cttatttaca taaaacaact gaagcgttag ctctatcaga ttccgagttt 300
actggaaaac tgtggtctct ataccttgct accttaaaat ctgcacagta caaaaagcag 360
aattttaggc taggtatatt tagatcacag tatttgattg ataagaaaaa gggtactgaa 420
cagattaagc aagtcctgtt tagtacattc tcagtggaat ttgcaggcct tagcgagaaa 480
gttgatagat tgcactctta tttaaatagg gcaaacaagt acgatcctaa aggaccaatt 540
tataatgatc aaaatatggt catttctgat tcaggatacc ttttgtctaa ggcattggcc 600
aaagctgtgg aatcgtataa gtcacaacaa agttcttcta caactagtga tcctattgtc 660
gcattcattg tgcaaagaaa catcagacat gtgtttactc aaaaggtctt ggaattgaat 720
ctgttggaaa aattcggtac caaatctgtt aggttgacgt ttgatgatgt taacgataaa 780
ttgttcattg atgataaaac gggaaagctt ttcattaggg acacagagca ggaaatagcg 840
gtggtttatt acgtaacggg ttacacaacc actgattaca cgtccgaaaa ggactgggag 900
gcaagactat tcctcgaaaa aagtttcgca ataaaggccc cagatttact cactcaatta 960
tctggctcca agaaaattca gcaattgttg acagatgagg gcgtattagg taaatacatc 1020
tccgatgctg agaaaaagag tagtttgtta aaaacttttg tcaaaatata tcccttggat 1080
gatacgaagc ttggcaggga aggcaagagg ctggcattaa gtgagccctc taaatacgtg 1140
ttaaaaccac agcgggaaaa tggcggaaac aatgtttata aagaaaatat tcctaatttt 1200
ttgaaaggta tcgaagaacg tcactgggat gcatatattc tcatggagtt gattgaacca 1260
gagttgaatg aaaataatat tatattacgt gataacaaat cttacaacga accaatcatc 1320
agtgaactag gagattatgg ttgcgttcta tttaacgacg agcaagtttt atcgaacgaa 1380
tttagtggct cattactaag atccaaattt aatacttcaa atgaaggtgg agtggcggca 1440
ggattcggat gtttggacag tattattctt tactag 1476
<210> 13
<211> 2793
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 13
atgacgcagg ccaaggaaaa catcttagtt gtggtcgatg gctactcctc aggcagtcag 60
ttgcctaccc tgatggcgga atccggctgg aagtgtgttc atgtctcgtc ctcggctaac 120
cccccggagt attacctgcg tacataccat aaggatgagt acatagctca ctttgagtat 180
caaggtgata tacagtcact tgctagtgct gttgaggcgt ggcatcccgc cgcagttctt 240
cctggtacga aaagtggagt tattgtcgct gatttactgg cggctgcttt gcaattgcca 300
ggcaatgacc cgtcgacctc cctggcgaga cgcgacaaat atacgatgca tgagtcattg 360
aaagcggtgg gacttcggag tatggaccat ttccttgccg tcgatcgtga tgctttatca 420
gcttgggccg agcggggatc ttggccagtg gtaattaaac cccaggcttc gcacgacaca 480
gacagtgtta cattctgcgc cgatcaggga gaattattag agtcgtttga tcaattgttc 540
ggcactgtga accaattggg tgaacgcaat aatgcagtgc tggctcagcg tctgttggtt 600
ggtcccgagt actttatcaa cggagtttct ggacatggca aacacctgat tacagagatt 660
tggcgtgcag acaagctgcc cgcaccggac gggggttgga tatacgaccg ggccgtgctg 720
tttgacccga tcagtcccga gatgcaggag attgtccgct acgtgcatgg agtattagat 780
gcccttggca tccgctatgg tgcgaaccat acagagctga tcgtaacggc tgatggccca 840
acactgatag aatgtgcctc ccgtttactc gggtggctgc atagacctgc agcgaactat 900
gcggttggcg catcacaact tgacttggtc ggtaaacttg tacgggaagg ggaaagcgct 960
atagatgata tactgcaaac ttggcaacct caccgctacg cattgtggca agtccaattc 1020
atatcgaatc aagagggagt agtggctcgg agttcgtacg acgaacttct taaaacgttg 1080
aaatccaatg cctggttgca acgggctccg aaggaaggcg ataccgtagt caagacagtc 1140
gacctgttca gctcgcccgg aatagtcttt atgtcacacg cagacggtaa tgttctgcac 1200
gacgattatc ggacggtccg ggaatgggag cgtacctcgc gcctgttctc ggtgcagggt 1260
ggtggtggat cagggggtgg gggttcaggc ggtggcggat ccggcggggg tggttccatg 1320
gcacactatc caccttccaa ggatcaattg aatgaattga tccaggaagt taaccaatgg 1380
gctatcacta atggattatc catgtatcct cctaaattcg aggagaaccc atcaaatgca 1440
tcggtgtcac cagtaactat ctatccaacc ccaattccta ggaaatgttt tgatgaggcc 1500
gttcaaatac aaccggtatt caatgaatta tacgcccgta ttacccaaga tatggcccaa 1560
cctgattctt atttacataa aacaactgaa gcgttagctc tatcagattc cgagtttact 1620
ggaaaactgt ggtctctata ccttgctacc ttaaaatctg cacagtacaa aaagcagaat 1680
tttaggctag gtatatttag atcacagtat ttgattgata agaaaaaggg tactgaacag 1740
attaagcaag tcctgtttag tacattctca gtggaatttg caggccttag cgagaaagtt 1800
gatagattgc actcttattt aaatagggca aacaagtacg atcctaaagg accaatttat 1860
aatgatcaaa atatggtcat ttctgattca ggataccttt tgtctaaggc attggccaaa 1920
gctgtggaat cgtataagtc acaacaaagt tcttctacaa ctagtgatcc tattgtcgca 1980
ttcattgtgc aaagaaacat cagacatgtg tttactcaaa aggtcttgga attgaatctg 2040
ttggaaaaat tcggtaccaa atctgttagg ttgacgtttg atgatgttaa cgataaattg 2100
ttcattgatg ataaaacggg aaagcttttc attagggaca cagagcagga aatagcggtg 2160
gtttattacg taacgggtta cacaaccact gattacacgt ccgaaaagga ctgggaggca 2220
agactattcc tcgaaaaaag tttcgcaata aaggccccag atttactcac tcaattatct 2280
ggctccaaga aaattcagca attgttgaca gatgagggcg tattaggtaa atacatctcc 2340
gatgctgaga aaaagagtag tttgttaaaa acttttgtca aaatatatcc cttggatgat 2400
acgaagcttg gcagggaagg caagaggctg gcattaagtg agccctctaa atacgtgtta 2460
aaaccacagc gggaaaatgg cggaaacaat gtttataaag aaaatattcc taattttttg 2520
aaaggtatcg aagaacgtca ctgggatgca tatattctca tggagttgat tgaaccagag 2580
ttgaatgaaa ataatattat attacgtgat aacaaatctt acaacgaacc aatcatcagt 2640
gaactaggag attatggttg cgttctattt aacgacgagc aagttttatc gaacgaattt 2700
agtggctcat tactaagatc caaatttaat acttcaaatg aaggtggagt ggcggcagga 2760
ttcggatgtt tggacagtat tattctttac tag 2793
<210> 14
<211> 2793
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 14
atgacgcagg ccaaggaaaa catcttagtt gtggtcgatg gctactcctc aggcagtcag 60
ttgcctaccc tgatggcgga atccggctgg aagtgtgttc atgtctcgtc ctcggctaac 120
cccccggagt attacctgcg tacataccat aaggatgagt acatagctca ctttgagtat 180
caaggtgata tacagtcact tgctagtgct gttgaggcgt ggcatcccgc cgcagttctt 240
cctggtacga aaagtggagt tattgtcgct gatttactgg cggctgcttt gcaattgcca 300
ggcaatgacc cgtcgacctc cctggcgaga cgcgacaaat atacgatgca tgagtcattg 360
aaagcggtgg gacttcggag tatggaccat ttccttgccg tcgatcgtga tgctttatca 420
gcttgggccg agcggggatc ttggccagtg gtaattaaac cccaggcttc gcacgacaca 480
gacagtgtta cattctgcgc cgatcaggga gaattattag agtcgtttga tcaattgttc 540
ggcactgtga accaattggg tgaacgcaat aatgcagtgc tggctcagcg tctgttggtt 600
ggtcccgagt actttatcaa cggagtttct ggacatggca aacacctgat tacagagatt 660
tggcgtgcag acaagctgcc cgcaccggac gggggttgga tatacgaccg ggccgtgctg 720
tttgacccga tcagtcccga gatgcaggag attgtccgct acgtgcatgg agtattagat 780
gcccttggca tccgctatgg tgcgaaccat acagagctga tcgtaacggc tgatggccca 840
acactgatag aatgtgcctc ccgtttactc gggtggctgc atagacctgc agcgaactat 900
gcggttggcg catcacaact tgacttggtc ggtaaacttg tacgggaagg ggaaagcgct 960
atagatgata tactgcaaac ttggcaacct caccgctacg cattgtggca agtccaattc 1020
atatcgaatc aagagggagt agtggctcgg agttcgtacg acgaacttct taaaacgttg 1080
aaatccaatg cctggttgca acgggctccg aaggaaggcg ataccgtagt caagacagtc 1140
gacctgttca gctcgcccgg aatagtcttt atgtcacacg cagacggtaa tgttctgcac 1200
gacgattatc ggacggtccg ggaatgggag cgtacctcgc gcctgttctc ggtgcagggt 1260
ggtgggggat ctgaggctgc ggctaaagag gcggcagcaa aaggaggagg cggaagcatg 1320
gcacactatc caccttccaa ggatcaattg aatgaattga tccaggaagt taaccaatgg 1380
gctatcacta atggattatc catgtatcct cctaaattcg aggagaaccc atcaaatgca 1440
tcggtgtcac cagtaactat ctatccaacc ccaattccta ggaaatgttt tgatgaggcc 1500
gttcaaatac aaccggtatt caatgaatta tacgcccgta ttacccaaga tatggcccaa 1560
cctgattctt atttacataa aacaactgaa gcgttagctc tatcagattc cgagtttact 1620
ggaaaactgt ggtctctata ccttgctacc ttaaaatctg cacagtacaa aaagcagaat 1680
tttaggctag gtatatttag atcacagtat ttgattgata agaaaaaggg tactgaacag 1740
attaagcaag tcctgtttag tacattctca gtggaatttg caggccttag cgagaaagtt 1800
gatagattgc actcttattt aaatagggca aacaagtacg atcctaaagg accaatttat 1860
aatgatcaaa atatggtcat ttctgattca ggataccttt tgtctaaggc attggccaaa 1920
gctgtggaat cgtataagtc acaacaaagt tcttctacaa ctagtgatcc tattgtcgca 1980
ttcattgtgc aaagaaacat cagacatgtg tttactcaaa aggtcttgga attgaatctg 2040
ttggaaaaat tcggtaccaa atctgttagg ttgacgtttg atgatgttaa cgataaattg 2100
ttcattgatg ataaaacggg aaagcttttc attagggaca cagagcagga aatagcggtg 2160
gtttattacg taacgggtta cacaaccact gattacacgt ccgaaaagga ctgggaggca 2220
agactattcc tcgaaaaaag tttcgcaata aaggccccag atttactcac tcaattatct 2280
ggctccaaga aaattcagca attgttgaca gatgagggcg tattaggtaa atacatctcc 2340
gatgctgaga aaaagagtag tttgttaaaa acttttgtca aaatatatcc cttggatgat 2400
acgaagcttg gcagggaagg caagaggctg gcattaagtg agccctctaa atacgtgtta 2460
aaaccacagc gggaaaatgg cggaaacaat gtttataaag aaaatattcc taattttttg 2520
aaaggtatcg aagaacgtca ctgggatgca tatattctca tggagttgat tgaaccagag 2580
ttgaatgaaa ataatattat attacgtgat aacaaatctt acaacgaacc aatcatcagt 2640
gaactaggag attatggttg cgttctattt aacgacgagc aagttttatc gaacgaattt 2700
agtggctcat tactaagatc caaatttaat acttcaaatg aaggtggagt ggcggcagga 2760
ttcggatgtt tggacagtat tattctttac tag 2793
<210> 15
<211> 861
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 15
atgccaatgg ttgctgcagt tgagttcgcc aaaagtccgg ccgaagtact gagggttgga 60
tcggggtttt cgctggcagg cgtggatccc gaatccacac ccggctacac cggtgtgaaa 120
gctgatggca aggcgttgct tgccgcgcag gacgcgcggc tggcggaact gcaggaaaag 180
ctcttcgccg aaggaaagtt cggcaacccc aaacggctcc tgctcatcct tcaggccatg 240
gatactgcgg gcaagggcgg cattgtcagc cacgttgttg gcgccatgga cccgcaaggc 300
gtacaactga ccgccttcaa agcgcctacg gacgaggaaa agtcgcacga cttcctctgg 360
agaatcgaaa aacaagtccc tgccgccgga atggtggggg tgttcgaccg ctcgcagtac 420
gaagacgtgc tgatccaccg tgtccatggc tgggcggacg ctgccgaact ggagcgccgg 480
tacgccgcga tcaacgactt tgagtcacgc ctgaccgagc agggaaccac catcgtcaag 540
gtcatgctca atatcagcaa ggacgaacag aaaaagcgtt tgatcgcccg gttggacgat 600
cccagcaagc actggaaata cagtcgcggc gacctcgcgg aacgtgcgta ctgggatgac 660
tacatggacg cctacagcgt tgccttcgag aagacctcca cagagattgc tccttggcac 720
gtggtgccgg caaacaagaa gtggtacgca cgcatcgcag tccagcaact gctgctggat 780
gccctcggcg gtttgcagct ggactggccc aaagctgact tcgatgtcgc cgctgagcgc 840
gccctcgtgg tggaatccta g 861
<210> 16
<211> 645
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 16
atgcgtatca ttctgcttgg cgctccgggc gcggggaaag ggactcaggc tcagttcatc 60
atggagaaat atggtattcc gcaaatctcc actggcgata tgctgcgtgc tgcggtcaaa 120
tctggctccg agctgggtaa acaagcaaaa gacattatgg atgctggcaa actggtcacc 180
gacgaactgg tgatcgcgct ggttaaagag cgcattgctc aggaagactg ccgtaatggt 240
ttcctgttgg acggcttccc gcgtaccatt ccgcaggcag acgcgatgaa agaagcgggc 300
atcaatgttg attacgttct ggaattcgac gtaccggacg aactgatcgt tgaccgtatc 360
gtcggtcgcc gcgttcatgc gccgtctggt cgtgtttatc acgttaaatt caatccgccg 420
aaagtagaag gcaaagacga cgttaccggt gaagaactga ctacccgtaa agatgatcag 480
gaagagaccg tacgtaaacg tctggttgaa taccatcaga tgacagcacc gctgatcggc 540
tactactcca aagaagcaga agcgggtaat accaaatacg cgaaagttga cggcaccaag 600
ccggttgctg aagttcgcgc tgatctggaa aaaatcctcg gctaa 645
<210> 17
<211> 20
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 17
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15
Gly Gly Gly Ser
20
<210> 18
<211> 20
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 18
Gly Gly Gly Gly Ser Glu Ala Ala Ala Lys Glu Ala Ala Ala Lys Gly
1 5 10 15
Gly Gly Gly Ser
20

Claims (8)

1.一种突变酶,其特征在于,包括甘氨酸和L-组氨酸连接酶GHS以及三肽连接酶HKS;或为两者的融合酶;
其中,所述甘氨酸和L-组氨酸连接酶GHS为在野生型L-氨基酸连接酶Lal基础上具有T244I、S290L、G292W、E84K、A158H、G159D位点突变的酶;所述三肽连接酶HKS为在野生型谷胱甘肽合成酶gshB基础上具有V150F、S153E、E228I、N230H、D233T、R285V、D130Q、E146L、N148S、G387、I445D位点突变的酶。
2.权利要求1所述突变酶在催化甘氨酸、L-组氨酸、L-赖氨酸生成三胜肽中的应用或在制备催化甘氨酸、L-组氨酸、L-赖氨酸生成三胜肽的酶制剂中的应用。
3.根据权利要求2所述应用,其特征在于,所述酶制剂为表达突变酶的宿主细胞、突变酶的酶液或突变酶的固定化酶。
4.一种酶催化法制备三胜肽的工艺,其特征在于,反应原料甘氨酸、L-组氨酸、L-赖氨酸、ATP或其盐,在权利要求1所述突变酶的pH值范围内的反应介质中,与权利要求1所述突变酶进行酶催化反应生成三胜肽。
5.根据权利要求4所述工艺,其特征在于,所述突变酶的pH值范围为6.5-9.0。
6.根据权利要求4所述工艺,其特征在于,所述反应介质为缓冲液。
7.根据权利要求4所述工艺,其特征在于,还包括添加反应原料PPK和ADK或两者融合蛋白、多聚磷酸、氯化镁和氯化钾。
8.根据权利要求4-7任意一项所述工艺,其特征在于,还包括选自除蛋白杂质、除残留反应原料、除盐、除磷酸和结晶中的一种或两种以上操作的纯化步骤。
CN202011231194.8A 2020-11-06 2020-11-06 一种突变酶及其应用和酶催化法制备三胜肽的工艺 Active CN112280755B (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202011231194.8A CN112280755B (zh) 2020-11-06 2020-11-06 一种突变酶及其应用和酶催化法制备三胜肽的工艺
EP21888289.2A EP4242300A1 (en) 2020-11-06 2021-09-09 Mutant enzyme, use thereof and process for preparing tripeptide by using enzymatic method
US18/035,736 US20230407286A1 (en) 2020-11-06 2021-09-09 Mutant enzyme, use thereof and process for preparing tripeptide by using enzymatic method
PCT/CN2021/117378 WO2022095590A1 (zh) 2020-11-06 2021-09-09 一种突变酶及其应用和酶催化法制备三胜肽的工艺

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011231194.8A CN112280755B (zh) 2020-11-06 2020-11-06 一种突变酶及其应用和酶催化法制备三胜肽的工艺

Publications (2)

Publication Number Publication Date
CN112280755A true CN112280755A (zh) 2021-01-29
CN112280755B CN112280755B (zh) 2023-03-14

Family

ID=74350947

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011231194.8A Active CN112280755B (zh) 2020-11-06 2020-11-06 一种突变酶及其应用和酶催化法制备三胜肽的工艺

Country Status (4)

Country Link
US (1) US20230407286A1 (zh)
EP (1) EP4242300A1 (zh)
CN (1) CN112280755B (zh)
WO (1) WO2022095590A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111979206A (zh) * 2019-05-24 2020-11-24 深圳瑞德林生物技术有限公司 固定化融合酶及用其制备谷胱甘肽的方法
CN113265382A (zh) * 2021-06-24 2021-08-17 洛阳华荣生物技术有限公司 多聚磷酸激酶突变体
WO2022095590A1 (zh) * 2020-11-06 2022-05-12 深圳瑞德林生物技术有限公司 一种突变酶及其应用和酶催化法制备三胜肽的工艺

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997738A (zh) * 2004-06-25 2007-07-11 协和发酵工业株式会社 二肽或二肽衍生物的制备方法
WO2008052428A1 (fr) * 2006-10-24 2008-05-08 Beijing Jenkem Technology Co. Ltd Procédé de preparation et conjugué avec molécule médicinale correspondante
CN104328092A (zh) * 2014-09-28 2015-02-04 邦泰生物工程(深圳)有限公司 一种谷胱甘肽合成酶突变体、编码基因及应用
CN110777123A (zh) * 2019-12-04 2020-02-11 深圳瑞德林生物技术有限公司 突变的l-氨基酸连接酶以及酶催化法制备l-谷氨酸-l-色氨酸二肽的工艺

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104059936B (zh) * 2014-04-30 2017-01-25 唐星 一种用于合成谷胱甘肽的基因工程菌的制备方法及其产品
CN112280755B (zh) * 2020-11-06 2023-03-14 深圳瑞德林生物技术有限公司 一种突变酶及其应用和酶催化法制备三胜肽的工艺

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997738A (zh) * 2004-06-25 2007-07-11 协和发酵工业株式会社 二肽或二肽衍生物的制备方法
WO2008052428A1 (fr) * 2006-10-24 2008-05-08 Beijing Jenkem Technology Co. Ltd Procédé de preparation et conjugué avec molécule médicinale correspondante
CN104328092A (zh) * 2014-09-28 2015-02-04 邦泰生物工程(深圳)有限公司 一种谷胱甘肽合成酶突变体、编码基因及应用
CN110777123A (zh) * 2019-12-04 2020-02-11 深圳瑞德林生物技术有限公司 突变的l-氨基酸连接酶以及酶催化法制备l-谷氨酸-l-色氨酸二肽的工艺

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
周桢等: "短肽衍生物的制备及其在日化领域的应用", 《日用化学品科学》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111979206A (zh) * 2019-05-24 2020-11-24 深圳瑞德林生物技术有限公司 固定化融合酶及用其制备谷胱甘肽的方法
WO2022095590A1 (zh) * 2020-11-06 2022-05-12 深圳瑞德林生物技术有限公司 一种突变酶及其应用和酶催化法制备三胜肽的工艺
CN113265382A (zh) * 2021-06-24 2021-08-17 洛阳华荣生物技术有限公司 多聚磷酸激酶突变体
CN113265382B (zh) * 2021-06-24 2023-11-10 洛阳华荣生物技术有限公司 多聚磷酸激酶突变体

Also Published As

Publication number Publication date
CN112280755B (zh) 2023-03-14
US20230407286A1 (en) 2023-12-21
EP4242300A1 (en) 2023-09-13
WO2022095590A1 (zh) 2022-05-12

Similar Documents

Publication Publication Date Title
CN112280755B (zh) 一种突变酶及其应用和酶催化法制备三胜肽的工艺
CN110777123B (zh) 突变的l-氨基酸连接酶以及酶催化法制备l-谷氨酸-l-色氨酸二肽的工艺
CN111321193B (zh) 一种生物多酶偶联法氧化还原不对称制备l-草铵膦的方法
CN111254129B (zh) 一种多聚磷酸激酶突变体及其应用
CN113151198B (zh) 一种γ-谷酰胺甲胺合成酶的突变体,其编码基因、氨基酸序列及其应用
CN112921023B (zh) 一种重组天冬氨酸裂解酶及高重复利用率用于制备r-3-氨基丁酸的方法
CN112368387A (zh) 通过发酵产生组胺的经改造的生物合成途径
CN116410938B (zh) β-丙氨酸连接酶突变体及其应用
CN111808829B (zh) 一种γ-谷氨酰甲胺合成酶突变体及其应用
CN111133105B (zh) D型氨基酸脱氢酶
CN105349557B (zh) 一种苹果酸酶基因rkme2及其重组表达载体
CN113388559A (zh) 一种用于谷胱甘肽合成的重组大肠杆菌及其应用
CN108239664B (zh) 一种制备4-羟基-l-苏氨酸的工艺
CN115992103A (zh) 酶突变体及类蛇毒三肽的制备方法
CN114875002B (zh) 一种精氨酸突变的dna/rna连接酶
CN112980821B (zh) 一种特异性识别底物的褐藻胶裂解酶突变体及其应用
CN112779236B (zh) 一种反式丁烯酸转氨酶工程菌及其高密度发酵方法和应用
CN111051508A (zh) D型氨基酸脱氢酶
CN113151199B (zh) 一种具有热稳定性的γ-谷酰胺甲胺合成酶的突变体,其编码基因、氨基酸序列及其应用
US20210238576A1 (en) L-aspartate alpha-decarboxylase Mutant and Application thereof
CN113881728B (zh) 7-氨甲基-7-脱氮鸟嘌呤(PreQ1)的制备方法
CN117511889B (zh) 酶及其在非天然氨基酸二肽制备中的应用
CN114657200B (zh) 重组工程菌及其用于制备d-泛解酸的方法
CN115058402B (zh) 一种烟酰胺核糖激酶突变体及其编码基因和应用
KR102016050B1 (ko) 신규한 프로모터 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 518000 floor 3, building 2, Shenzhen biological incubation base, No. 10, Gaoxin Zhongyi Road, Maling community, Yuehai street, Nanshan District, Shenzhen, Guangdong

Applicant after: SHENZHEN READLINE BIOTECHNOLOGY Co.,Ltd.

Address before: 518057 Room 101, 1st floor, building 2, Shenzhen biological incubation base, No.10, Gaoxin middle 1st Road, Maling community, Yuehai street, Nanshan District, Shenzhen City, Guangdong Province

Applicant before: SHENZHEN READLINE BIOTECHNOLOGY Co.,Ltd.

GR01 Patent grant
GR01 Patent grant